key: cord-0027879-bmq45vhy
authors: Zhang, Qian; Wu, Lei
title: In Vitro and In Vivo Cardioprotective Effects of Curcumin against Doxorubicin-Induced Cardiotoxicity: A Systematic Review
date: 2022-02-21
journal: J Oncol
DOI: 10.1155/2022/7277562
sha: b76a848a59f3447302fc2404bb9280950d96d313
doc_id: 27879
cord_uid: bmq45vhy

OBJECTIVE: This study aimed to review the potential chemoprotective effects of curcumin against the doxorubicin-induced cardiotoxicity. METHODS: According to the PRISMA guideline, a comprehensive systematic search was performed in different electronic databases (Web of Science, PubMed, and Scopus) up to July 2021. One hundred and sixty-four studies were screened in accordance with a predefined set of inclusion and exclusion criteria. Eighteen eligible articles were finally included in the current systematic review. RESULTS: According to the in vitro and in vivo findings, it was found that doxorubicin administration leads to decreased cell survival, increased mortality, decreased bodyweight, heart weight, and heart to the bodyweight ratio compared to the control groups. However, curcumin cotreatment demonstrated an opposite pattern in comparison with the doxorubicin-treated groups alone. Other findings showed that doxorubicin significantly induces biochemical changes in the cardiac cells/tissue. Furthermore, the histological changes on the cardiac tissue were observed following doxorubicin treatment. Nevertheless, for most of the cases, these biochemical and histological changes mediated by doxorubicin were reversed near to control groups following curcumin coadministration. CONCLUSION: It can be mentioned that coadministration of curcumin alleviates the doxorubicin-induced cardiotoxicity. Curcumin exerts these cardioprotective effects through different mechanisms of antioxidant, antiapoptosis, and anti-inflammatory. Since the finding presented in this systematic review are based on in vitro and in vivo studies, suggesting the use of curcumin in cancer patients as a cardioprotector agent against cardiotoxicity mediated by doxorubicin requires further clinical studies.

For many years, cardiovascular anomalies are considered as the leading cause of death in the worldwide; therefore, cardiotoxicity has become a crucial concern for scientific community [1, 2] . Literature supports that severe cardiotoxicity is commonly evident in antitumor treatments [3] [4] [5] [6] [7] [8] ; hence, even if these patients survive from malignant tumor, they end up with heart complications in longer run that lead to compromised life style or death [9] . In this regard, drug-induced cardiotoxicity has withdrawn much attention in past two decades, as it has led to ban on various classes of drugs (such as rosiglitazone, prenylamine, rofecoxib, and levomethadyl acetate) due to their associated severe cardiotoxicity [10] [11] [12] [13] . Nevertheless, there are still some cardiotoxic drugs that are applied by clinicians either other safer alternatives are not available or these drugs outweigh the risk of cardiac deformities. Doxorubicin (adriamycin) is an effective chemotherapy drug which belongs to nonselective class I anthracycline family [14] . is chemotherapeutic agent is widely applied for the treatment of different cancers, such as acute leukemia, lymphomas, lung cancer, testicular cancer, thyroid cancer, ovarian cancer, breast cancer, and so on [15] [16] [17] [18] [19] . Major limitation reported for doxorubicin is the associated toxicity on various body organs, particularly the heart [9] . e doxorubicin-induced cardiotoxicity can manifest as aberrant arrhythmias, congestive heart failure, and ventricular dysfunction [20] [21] [22] . It has been also reported that the doxorubicin-induced cardiomyopathy has poor prognosis and can lead to death in most of the cases [17, 23] . Fortunately, the mentioned adverse effects overcome through combination chemotherapy [24, 25] . In this regard, coadministration of doxorubicin with other agents having chemoprotective capabilities can diminish the toxicity to normal tissues and enhance the tumoricidal efficacy of doxorubicin at the same time [26, 27] .

According to the published studies, it can be stated that using the herbal and natural compounds or their derivatives to alleviate the adverse effects induced by radiotherapy/ chemotherapy agents (radio/chemoprotectors) and/or increase the sensitivity of tumoral cells to radiotherapy/chemotherapy agents (radio/chemosensitizers) has attracted much attention over the past several decades [28] [29] [30] [31] . Curcumin is a vibrant yellow spice extracted from rhizome of turmeric (Curcuma longa) that is insoluble in water [32, 33] . is natural polyphenol is a main active component of turmeric [34] that has antioxidant [35, 36] , antiapoptotic [37] , anti-inflammatory [38] [39] [40] , hepatoprotective [41, 42] , analgesic and antiarthritic [43, 44] , pulmonoprotective [45] , lipid-modifying [46, 47] , immunomodulatory [48, 49] , and antidiabetic [50, 51] actions. Curcumin also has anticancer activity, and it has been assessed in different malignant tumors, including colorectal cancer, prostate cancer, lung cancer, gastric cancer, breast cancer, and so on [52] . Moreover, this herbal agent can be used as an adjuvant in combination with other cancer therapeutic modalities such as radiotherapy and chemotherapy [32, 53] . In this regard, curcumin is able to alleviate the radiotherapy/chemotherapy-induced adverse effects (radio/chemoprotectors) and/or increase the sensitivity of cancer cells to radiotherapy/ chemotherapy drugs (radio/chemosensitizers) which exerts the mentioned effects through the antiproliferative, antioxidant, antiapoptotic, and anti-inflammatory activities.

To the best of our knowledge, the present study is the first systematic review on the cardioprotective effects of curcumin, as an adjuvant, against doxorubicin-induced cardiotoxicity. In this regard, we tried to answer the following questions: (a) How does doxorubicin chemotherapy drug lead to cardiac adverse effects? (b) What are the underlying mechanisms of cardiotoxicity induced by doxorubicin? (c) What is the role of curcumin on the doxorubicin-induced cardiotoxicity? (d) What are the cardioprotective mechanisms of curcumin against doxorubicin-induced cardiotoxicity?

In this study, a systematic search was done in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline [54] . Furthermore, a PICO framework was used to structure the review process [54] . is framework includes participants (P): cardiac cells damaged by doxorubicin (in vitro studies) and/or patients/ animals with cardiac adverse effects induced by doxorubicin (clinical/in vivo studies); intervention (I): patients/animals/ cells treatment with doxorubicin chemotherapeutic drug; comparison (C): patients/animals/cells treated with curcumin and doxorubicin; outcomes (O): there were two critical outcomes: changes induced in the cardiac cells/tissue following doxorubicin treatment compared to control/untreated groups and changes resulted in the cardiac cells/tissue following combined treatment of curcumin and doxorubicin in comparison with doxorubicin treatment alone.

We performed a comprehensive systematic search for obtaining all relevant studies on "the role of curcumin on doxorubicin-induced cardiotoxicity" in both medical subject heading (MeSH) or advance in the electronic databases of Scopus, PubMed, and Web of Science up to July 2021 using the keywords of "Doxorubicin" OR "Adriamycin" AND "Curcumin" AND "Heart" OR "Cardiac" OR "Cardiac Toxicity" OR "Cardiac Toxicities" OR "Cardiomyopathy" OR "Arrhythmias" OR "Myocardium" OR "Myocardial" OR "Myocyte" OR "Cardiomyocyte" OR "Cardiopathic" OR "Cardiopathy" OR "Cardiotoxicity" OR "Cardiotoxicities" in title, abstract, or keywords.

e inclusion criteria considered in this systematic review were full-text scientific studies with English language; our per-defined aim on the role of curcumin on doxorubicin-induced cardiotoxicity (based on the aforementioned keywords); adequate findings; no restriction in publications with clinical, in vivo, or in vitro studies; and no restriction on publication year. Additionally, the exclusion criteria considered for this study were hemodynamic data, not related articles, review papers, case reports, book chapters, letters to the editors, oral presentations, posters, and editorials.

Each eligible study was evaluated by two researchers, and the following data were then extracted: author name and year of publication; models (clinical, in vivo or/and in vitro); doxorubicin dosage, protocol of usage, and administration route type; outcomes of doxorubicin on cardiac cells/tissue; curcumin dosage, protocol of usage, and administration route type; and curcumin coadministration outcomes.

e study selection process is shown in Figure 1 .

One hundred and sixty-four articles were obtained by a comprehensive and systematic search on the electronic databases mentioned above up to July 2021. After removing the duplicated articles (n � 77), the remaining ones (n � 87) were screened in their titles and abstracts. After that, 46 articles were excluded, and remaining ones (n � 41) were qualified for evaluation of their full-texts. Eighteen articles were finally included in this systematic review based on the abovementioned inclusion and exclusion criteria. Table 1 provides a summary of the findings extracted from the eligible articles.

Doxorubicin-Induced Cardiotoxicity 3.2.1. Cell Survival and Mortality. According to the in vitro results, it was found that the cardiac cell survival following doxorubicin treatment was significantly lower than the untreated/control group [2, 9, [55] [56] [57] . Furthermore, the doxorubicin-mediated cytotoxicity was dose and time-dependent. It showed a direct relation between the cell death and posttreatment time/chemotherapy dosage [55, 56] . In contrast, the findings revealed that cotreatment of curcumin resulted to protect the cardiac cells against doxorubicininduced decrease in cell viability [2, 9, 57] . However, a number of studies have shown that combined treatment of curcumin and doxorubicin leads to a further reduction in cell viability than doxorubicin-treated groups alone [55, 56] . e results of in vivo studies demonstrated that the mortality in doxorubicin-treated rats was significantly more than the untreated/control group [58] [59] [60] . e use of curcumin significantly decreased doxorubicin-induced mortality [58] [59] [60] . For instance, Imbaby et al. reported the survival rates of 58.33%, 66.33%, and 91.66% in the animals treated by doxorubicin, doxorubicin plus curcumin 100 mg/ kg, and doxorubicin plus curcumin 200 mg/kg [59] .

Weight. Some studies showed that the bodyweight and heart weight and ventricle weight, and volume of animals treated by doxorubicin were less than the control group [58] [59] [60] [61] [62] [63] . It was also reported that ratio of heart to the bodyweight of mice/rats were reduced following doxorubicin administration than the control group [60, 63] .

Coadministration of curcumin and doxorubicin to the mice/rats led to increase the bodyweight, heart weight, ventricle weight and volume, and ratio of heart to bodyweight in comparison with the doxorubicin-treated groups alone [58] [59] [60] [61] [62] [63] .

e biochemical changes induced on heart cells/tissue can be observed following the doxorubicin treatment, as given in Table 1 Figure 1 : Flow diagram of PRISMA applied in the current study for the selection process. Journal of Oncology , thiobarbituric acid reactive substances (TBARS), alanine aminotransferase (ALT), alkaline phosphatase (ALP), nitric oxide (NO), inducible nitric oxide synthase (iNOS), Bcl-2-associated X protein (BAX), BAX to B cell lymphoma 2 (Bcl-2) ratio, caspases-1, 2, 3, and 9, creatine phosphokinase (CPK), creatine kinase-myocardial band (CK-MB), nuclear factor-kappa B (NF-κB), cyclooxygenase-2 (COX-2), LC3II to LC3I ratio, Beclin1, troponin I, troponin-T, interleukin 1 beta (IL-1β), IL-6, IL-18, tumor necrosis factor alpha (TNF-α), interferon gamma (INF-c), monocyte chemoattractant protein-1 (MCP-1), early growth response protein-1 (Egr1), and NLR family pyrin domain containing 3 (NLRP3) levels were significantly increased in the doxorubicintreated groups compared to the control groups [2, [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] . In contrast, the glutathione peroxidase (GPx), glutathione (GSH), mammalian target of rapamycin (mTOR) phosphorylation, and phospho-Akt levels were significantly reduced following the doxorubicin administration compared to the control groups [57-60, 63, 65, 66, 68-70] . e findings also showed that the curcumin cotreatment alleviated doxorubicin-induced biochemical alterations on heart cells/tissue (for most of the cases) [2, [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] . Nevertheless, it was found that the curcumin cotreatment synergized the effects of doxorubicin on several biochemical markers (for instance, ROS, superoxide dismutase (SOD), BAX, Bcl-2, and caspases-2, 3, and 9) [2, 55-57].

As given in Table 1 , there were conflicting findings on several biochemical markers. In this regard, several studies reported the elevated levels of catalase, SOD, and Bcl-2 following doxorubicin treatment alone [2, 57, 65] , while other studies reported the decreased levels for these biomarkers [2, 56-60, 62, 66, 68, 70] ; however, combined treatment of curcumin and doxorubicin alleviated the changes induced by doxorubicin on these biochemical markers [2, 57-60, 62, 65, 66, 68, 70] .

e obtained data from histological assessment of the doxorubicin-treated mice/rats showed the following histological changes: loss of myofibrils, cytoplasmic vacuolization, degeneration of cardiac muscle fibers, interstitial edema, increase in percentage of injured cells, reduction in cardiomyocyte population, severe hemorrhage, inflammatory cell infiltration, cellular swelling, spotted necrosis, interstitial cell hypertrophy, atrophic changes in myocardium and vessels, fibrous tissue formation, wavy degeneration of cardiac muscle fibers, damaged mitochondria, and so on [2, [57] [58] [59] [60] [61] [62] 68 ].

e results of most studies demonstrated that coadministration of curcumin and doxorubicin could alleviate the doxorubicin-induced histological changes [2, 57-62, 68]. 

In the current study, we aimed to review the doxorubicininduced adverse effects on the cardiac cells/tissue. Additionally, the coadministration effects of curcumin on these adverse effects were reviewed. e findings obtained from the effects of doxorubicin treatment alone or in combination with curcumin on the cardiac cells/tissue are given in Table 1 . Moreover, some of the important changes on the cardiac cell following doxorubicin administration as well as the effects of curcumin coadministration on these changes are shown in Figure 2 . Doxorubicin, a chemotherapeutic drug belonging to the anthracycline group, is highly effective in the treatment of a variety of malignant tumors [71] . e mechanisms of action for doxorubicin cytotoxic effects in cancerous cells include DNA intercalation leading to topoisomerase II disruption as well as generation of ROS resulting in cell membrane and mitochondrial membrane damage [17, 72] . Nevertheless, the clinical use of doxorubicin is restricted by the risk of dosedependent cardiotoxicity [62] . A variety of mechanisms for explanation of doxorubicin-induced cardiomyopathy have been proposed, including oxidative stress, inflammation, apoptosis, iron-loading disorders, and calcium dysregulation [73] . It has been suggested that the use of chemoprotective agents (such as curcumin) can mitigate the doxorubicin-induced cardiotoxicity. e antitumoral activity of curcumin has been reported in some cancers [52] . Moreover, this natural phytochemical agent has multiple biological activities including chemosensitizing properties [74, 75] and chemoprotection effects [76, 77] . Curcumin exerts its chemoprotective effects through its antioxidant, antiapoptotic, anti-inflammatory activities, and so on. In the following subsections, the mechanistic effects of the doxorubicin chemotherapeutic agent on the cardiac cellular pathway and the mechanistic effects of curcumin against the cardiac adverse effects induced by doxorubicin are discussed.

Normally, free radicals are produced in the cells in which the relevant defense mechanisms protect the cells against them [78, 79] . Of note, the free radicals increase in oxidative stress conditions because an imbalance between the free radicals and these defense systems occurs [80, 81] . Some studies have reported that the doxorubicin administration increases the ROS level of cardiac cells. e ROS attacks the cell macromolecules and leads to malfunction of the heart tissue [2, 56, 57, 64] . It also showed that upon mitochondrial damage, the generation of free radicals increases in the cells [82] ; in this regard, doxorubicin through impairment of mitochondrial function can elevate the generation of free radicals [2, 64, 83] . Moreover, this chemotherapeutic agent is able to increase : e molecular mechanisms of cardiac adverse effects mediated by doxorubicin. Mostly, doxorubicin induces oxidative stress through mitochondrial dysfunction. is chemotherapy agent increases free radicals via inhibition of GSH and GPx and also elevates LPO markers (MDA and TBARS). Furthermore, doxorubicin increases the apoptosis process through increments in BAX and caspase-1 activities. Moreover, doxorubicin elevates the inflammatory mediators (such as NF-κB, COX-2, TNF-α, INF-c, IL-1β, IL-6, and IL-18) leading to the cell injury. Curcumin, through an opposite pattern (antioxidant, antiapoptotic, and anti-inflammatory activities), alleviates these doxorubicin-induced cardiac adverse effects. ↑, increased by doxorubicin; ↓, decreased by doxorubicin; BAX, Bcl-2-associated X protein; GSH, glutathione; GPx, glutathione peroxidase; IL-1β, interleukin 1 beta; LPO, lipid peroxidation; MDA, malondialdehyde; TBARS, thiobarbituric acid reactive substances; NF-κB, nuclear factor-kappa B; COX-2, cyclooxygenase-2; INF-c, interferon gamma; TGF-β1, transforming growth factor beta 1; and TNF-α, tumor necrosis factor alpha. the LPO level and decrease the GPx and GSH levels in the heart cells which lead to the cell membrane devastation and malfunction [57-60, 65, 66, 68-70] . Hydrogen peroxide (H 2 O 2 ), as a nonradical ROS, produces 2H 2 O via the activity of GPx enzyme and consuming GSH [84] . According to these findings, it can be mentioned that doxorubicin impairs free radical scavenging capacity of intracellular antioxidant enzymes. Furthermore, there is normally a low amount of NO in the cardiac cells [85] in which its level is increased following doxorubicin treatment [59] . It is noteworthy that NO has remarkable roles in cellular signaling during pathological processes [86, 87] . It was also found that doxorubicin leads to increase the O − 2 level in cardiac cells [63] . Interaction of NO with O − 2 generates ONOO − that is a potential free radical [88] .

e ONOO − can also turn to NO − 2 , NO − 3 , OH − , and CO − 3 . erefore, O − 2 can induce generation of reactive nitrogen species (RNS) [85] . Another study has reported increased expression of 8-OHdG and 3,3′-dityrosine (as biomarkers of oxidative damage) in the hearts of the rats treated by doxorubicin [68] .

It has been shown that curcumin through its antioxidant effects can help scavenging of free radicals generated by some chemotherapeutic agents, resulting to ameliorate toxic effects of chemotherapy [89] . e results represented in the current study revealed that curcumin could decline the doxorubicin-elevated ROS level of cardiac cells [57, 64] . However, it was also found that this herbal agent had a synergistic effect on the doxorubicin-generated ROS level in a concentration-dependent manner [56] . Moreover, Jain and Rani [2] reported that curcumin response on the doxorubicin-induced ROS level in cardiomyoblasts was dependent on mode of treatment, as the cells pretreated with curcumin for one day followed by doxorubicin treatment could decrease the doxorubicin-generated ROS level, while it was increased in the cells simultaneously treated with curcumin and doxorubicin [2] . is antioxidant agent could also reduce doxorubicin-induced mitochondria injury, thereby, inhibiting doxorubicin-induced ROS generation [64] . Moreover, the increased levels of NO and O − 2 following doxorubicin treatment were declined by the curcumin cotreatment [59, 63] . Furthermore, the combined treatment of curcumin and doxorubicin (compared to doxorubicin treatment alone) could upregulate GSH and GPx expressions [57-60, 65, 66, 68-70] and downregulate MDA, TBARS, 8-OHdG, and 3,3′-dityrosine levels in the cardiac cells [57, 58, 60, 63, 65, 68, 70] .

Apoptosis (or programmed cell death) induced by doxorubicin is beneficial in cancer treatment; nevertheless, the apoptotic effect of this chemotherapeutic agent in cardiac cells is responsible for its cardiotoxicity [90] . Some important mediators involved in the apoptosis process are caspase enzymes, cleaved poly (ADP-ribose) polymerase (PARP), Bcl-2, p53, BAX, B cell lymphoma-extra large (Bcl-xL), NFAT5, and ceramide [85, [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] . Moreover, the apoptosis process can occur following the massive DNA damage and the oxidative stress conditions [101, 102] . Some studies have showed that the using doxorubicin elevates the apoptosis level in the cardiac cells compared to the control groups [56, 57, 62, 64, 70] . Doxorubicin can also downregulate Bcl-xL expression [103] and upregulate BAX, cleaved caspases-1, 2, 3, and 9, and p53 expressions in the cardiac cells than the untreated groups [2, 55-57, 62, 63, 68, 104, 105] . ese findings demonstrate that the cells are moving towards apoptosis. Furthermore, doxorubicin impedes matrix metalloproteinase (MMP), mediates mitochondrial swelling, and opens mitochondrial permeability transition pore (mPTP), leading to apoptosis [106] . It has been also reported that doxorubicin can elevate PARP activity [107] [108] [109] . is nuclear enzyme (PARP) is able to regulate many cellular processes, including apoptosis, DNA repair, genomic stability, and chromatin functions [85, 110] .

e findings from other studies showed that doxorubicin can trigger cardiac apoptosis via activation of p53, c-Jun N-terminal kinases (JNKs), and p38 mitogenactivated protein kinases (MAPKs) pathways [111] .

Although curcumin can induce apoptosis in cancerous cells [112] [113] [114] [115] , it is also able to protect normal cells/tissues during cancer chemotherapy through its antiapoptotic effects [76, 116] . e data represented in this systematic review showed that combined treatment of curcumin and doxorubicin results to decrease the apoptosis level of cardiac cells in comparison with the doxorubicin-treated groups alone [57, 62, 64, 70] . It was also found that curcumin had a synergistic effect on the doxorubicin-induced apoptosis level in a dose-dependent manner [56] . Additionally, mode of treatment (as pretreatment or concomitant) affected the curcumin response to doxorubicin-induced apoptosis in cardiomyoblasts; in this regard, it was found that the cardiac cells pretreated with curcumin for one day followed by doxorubicin treatment showed a decrease in the apoptosis level induced by doxorubicin, while the apoptosis level was increased in the cells simultaneously treated with curcumin and doxorubicin [2] . e pretreatment of cardiac cells with curcumin followed by doxorubicin prevented loss of MMP and decreased mPTP opening [57] . Furthermore, curcumin combined to doxorubicin could modulate the expression of antiapoptotic (Bcl-2) and proapoptotic (BAX and caspases-1, 2, 3, 8, and 9) mediators in the cardiac cells treated by doxorubicin [2, 55-57, 62, 63, 68] .

e chemotherapy treatment can lead to trigger the inflammatory process [117] . e disorder of inflammatory pathways play a vital role in cancer development [118] . It is also responsible for the incidence of various adverse effects following chemotherapy. [32] e use of doxorubicin during cancer chemotherapy can induce heart inflammation [119, 120] . Furthermore, oxidative stress induced by doxorubicin can affect LPO and activate lysosomal enzymes which lead to promotion of the inflammation in heart tissue [85] . e doxorubicin-treated cardiac cells showed an increased production of proinflammatory medicators such as ROS, NF-κB, COX-2, TNF-α, INF-c, TGF-β, IL-1β, IL-6, and IL-18 levels [56, 63, 68, 121] . NF-κB, as a proinflammatory transcription factor, has a key role in the activation of TNF-α, IL-1β, IL-1, IL-2, IFNc, COX-2, and iNOS [122] [123] [124] . ese inflammatory cytokines are able to induce remarkable pathological changes in the form of transmural myocarditis, biventricular fibrosis, and cardiomyopathy [125] . IL-1 is a cytokine well associated to chronic and acute inflammation and other chronic diseases such as cardiomyopathy. It has been also reported that IL-1β, one of the members of the IL-1 family, exacerbates myocardial injures in cancer patients treated with chemotherapy drugs; hence, pharmacological inhibition of IL-1β can be considered as a promising approach for reduction of chemotherapy-induced adverse cardiovascular events [126] . TGF-β is a profibrogenic cytokine that mediates several aspects of the fibrotic process; for instance, it can induce fibroblast proliferation and transformation to myofibroblasts, causing the deposition of collagen and extracellular matrix protein [127, 128] . Additionally, TGF-β can modulate cell proliferation, differentiation, apoptosis, and migration [129] .

Several studies have reported that curcumin can be suggested as a promising anti-inflammatory agent [40, 130] . Curcumin, through its anti-inflammatory activities, can decrease the resistance of cancer cells to chemotherapeutic drugs and also protect the normal cells against chemotherapyinduced side effects [32] . According to the finding obtained from previous studies, it was shown that curcumin cotreatment alleviates the doxorubicin-induced cardiac inflammation. In details, it can be mentioned that combined treatment of curcumin and doxorubicin declines the elevated levels of NF-κB, COX-2, TNF-α, INF-c, IL-1β, IL-6, and IL-18 in the cardiac cells of the doxorubicin-treated animals [56, 62, 68] . Furthermore, the findings of histological examinations demonstrated that doxorubicin-induced cardiac inflammation is mitigated by curcumin coadministration [2, [57] [58] [59] [60] [61] [62] 68 ].

Because of its potent anticancer activities, doxorubicin is widely applied to treat cancer patients; however, irreversible cardiotoxic effects of this chemotherapeutic drug have limited its clinical applications. e published data demonstrated that using the chemoprotective agent of curcumin can alleviate the doxorubicin-induced cardiotoxicity. e researchers have reported several mechanisms for cardioprotective effects of curcumin against doxorubicin-induced cardiotoxicity, including antioxidant, antiapoptosis, anti-inflammatory, and so on. In addition to its chemoprotective, curcumin through chemosensitizer effects can sensitize cancer cells to chemotherapy drugs. e findings obtained for cardioprotective effects of curcumin against doxorubicin-induced cardiotoxicity are based on nonclinical studies (in vitro and in vivo models). erefore, suggesting the use of curcumin in cancer patients as a cardioprotector agent against cardiotoxicity mediated by doxorubicin or other chemotherapeutic drugs requires further clinical studies because sometimes the findings may be different between the in vitro and in vivo models and clinical studies.

ere are several limitations which should be addressed: (1) remarkable heterogeneity was encountered perhaps due to various regimens, doses, duration, center settings, and populations enrolled, calling for cautious interpretation of the data, (2) several studies suffer from significant sources of bias, and (3) the effects of doxorubicin treatment alone or in combination with curcumin on the cardiac cells/tissue in many occasions were assessed by very few studies; hence, the evidence to support it is low.

e data presented in this systematic review reveal that the doxorubicin chemotherapeutic agent induces biochemical and histological changes on the cardiac cells/tissue, leading to cardiac adverse effects. It has been also shown that the curcumin cotreatment alleviates the doxorubicin-mediated cardiotoxicity. Mechanically, curcumin exerts its cardioprotective effects through several main mechanisms, such as antioxidant, antiapoptosis, and anti-inflammatory.

e data used to support the findings of this study are available from the corresponding author upon request.

Not applicable.

Association between insulin resistance and the development of cardiovascular disease

Mode of treatment governs curcumin response on doxorubicin-induced toxicity in cardiomyoblasts

Cardiovascular effects of systemic cancer treatment

Cancer therapy-induced cardiac toxicity in early breast cancer

Late cardiac effects of cancer treatment

Cancer drugs and the heart: importance and management

Cardiotoxicity and oncological treatments

Update on cardiotoxicity of anti-cancer treatments

Assessment of herb-drug synergy to combat doxorubicin induced cardiotoxicity

Rosiglitazone: what went wrong

e significance of mitochondrial toxicity testing in drug development

Cardionomics: a new integrative approach for screening cardiotoxicity of drug candidates

Withdrawal of COX-2 selective inhibitors rofecoxib and valdecoxib: impact on NSAID and gastroprotective drug prescribing and utilization

Doxorubicin: the good, the bad and the ugly effect

e anthracyclines: will we ever find a better doxorubicin?

Role of anthracyclines in the era of targeted therapy

Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies

Doxorubicin-induced cardiomyopathy

Doxorubicin cardiomyopathy

Adriamycin-induced heart failure: mechanism and modulation

Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy

Cardiac toxicity of anticancer agents

Doxorubicin-induced cardiomyopathy

Current concepts for the management of head and neck cancer: chemotherapy

Cost-effectiveness of adding cetuximab to platinum-based chemotherapy for first-line treatment of recurrent or metastatic head and neck cancer

e combination of olaratumab with doxorubicin and cisplatinum regresses a chemotherapy-resistant osteosarcoma in a patient-derived orthotopic xenograft mouse model

Photodynamic synergistic effect of pheophorbide a and doxorubicin in combined treatment against tumoral cells

erapeutic potentials of resveratrol in combination with radiotherapy and chemotherapy during glioblastoma treatment: a mechanistic review

Polydatin reduces cardiotoxicity and enhances the anticancer effects of sunitinib by decreasing pro-oxidative stress, pro-inflammatory cytokines, and NLRP3 inflammasome expression

e radioprotective effects of alpha-lipoic acid on radiotherapyinduced toxicities: a systematic review

e role of melatonin on radiation-induced pneumonitis and lung fibrosis: a systematic review

Curcumin as an anti-inflammatory agent: implications to radiotherapy and chemotherapy

e role of curcumin/curcuminoids during gastric cancer chemotherapy: a systematic review of non-clinical study

e role of the vascular endothelial growth factor/vascular endothelial growth factor receptors axis mediated angiogenesis in curcumin-loaded nanostructured lipid carriers induced human HepG2 cells apoptosis

Antioxidant effects of curcuminoids in patients with type 2 diabetes mellitus: a randomized controlled trial

Effect of curcuminoids on oxidative stress: a systematic review and meta-analysis of randomized controlled trials

Curcumin improves outcomes and attenuates focal cerebral ischemic injury via antiapoptotic mechanisms in rats

Curcumin: an effective inhibitor of interleukin-6

Curcumin as a natural regulator of monocyte chemoattractant protein-1

Curcumin downregulates human tumor necrosis factor-α levels: a systematic review and meta-analysis of randomized controlled trials

Efficacy and safety of phytosomal curcumin in non-alcoholic fatty liver disease: a randomized controlled trial

Is there a role for curcumin supplementation in the treatment of non-alcoholic fatty liver disease? e data suggest yes

Curcuminoid treatment for knee osteoarthritis: a randomized double-blind placebo-controlled trial

Analgesic efficacy and safety of curcuminoids in clinical practice: a systematic review and meta-analysis of randomized controlled trials

Curcumin use in pulmonary diseases: state of the art and future perspectives

Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel

Effects of curcumin on HDL functionality

erapeutic effects of curcumin in inflammatory and immune-mediated diseases: a nature-made jackof-all-trades?

Curcumin: a natural modulator of immune cells in systemic lupus erythematosus

Effects of curcuminoids plus piperine on glycemic, hepatic and inflammatory biomarkers in patients with type 2 diabetes mellitus: a randomized double-blind placebo-controlled trial

erapeutic potential of curcumin in diabetic complications

Curcumin and cancer

Mechanisms of apoptosis modulation by curcumin: implications for cancer therapy

Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement

Effect of curcumin on doxorubicin-induced cytotoxicity in H9c2 cardiomyoblast cells

Curcumin potentiates doxorubicin-induced apoptosis in H9c2 cardiac muscle cells through generation of reactive oxygen species

Curcumin attenuates doxorubicin-induced cardiotoxicity via suppressing oxidative stress and preventing mitochondrial dysfunction mediated by 14-3-3c

Cardioprotective effect of curcumin against doxorubicin-induced myocardial toxicity in albino rats

Cardioprotective effects of curcumin and nebivolol against doxorubicin-induced cardiac toxicity in rats

Curcumin loaded mesoporous silica nanoparticles: assessment of bioavailability and cardioprotective effect

Cardioprotective effects of curcumin and carvacrol in doxorubicin-treated rats: stereological study

Zn(ii)-Curcumin supplementation alleviates gut dysbiosis and zinc dyshomeostasis during doxorubicin-induced cardiotoxicity in rats

Curcumin suppresses doxorubicin-induced cardiomyocyte pyroptosis via a PI3K/ Akt/mTOR-dependent manner

Efficacy of antioxidants as a Complementary and Alternative Medicine (CAM) in combination with the chemotherapeutic agent doxorubicin

Curcumin attenuation of acute adriamycin myocardial toxicity in rats

Combined cardioprotective effects of quercetin and curcumin on doxorubicin induced cardiotoxicity in rats

e role of Curcuma longa against doxorubicin (Adriamycin)-induced toxicity in rats

Curcumin ameliorates doxorubicin-induced cardiotoxicity by abrogation of inflammation, apoptosis, oxidative DNA damage, and protein oxidation in rats

Beneficial effects of curcumin on antitumor activity and adverse reactions of doxorubicin

Curcumin downregulates phosphate carrier and protects against doxorubicin induced cardiomyocyte apoptosis

Metabolic aspects of anthracycline cardiotoxicity

Doxorubicin induced heart failure: phenotype and molecular mechanisms

Molecular mechanism of doxorubicininduced cardiomyopathy-an update

Curcumin mediates chemosensitization to 5-fluorouracil through miRNA-induced suppression of epithelial-to-mesenchymal transition in chemoresistant colorectal cancer

Curcumin chemosensitizes 5-fluorouracil resistant MMR-deficient human colon cancer cells in high density cultures

Chemoprotective effects of curcumin on doxorubicin-induced nephrotoxicity in wistar rats: by modulating inflammatory cytokines, apoptosis, oxidative stress and oxidative DNA damage

Effects of the antioxidants curcumin or selenium on cisplatin-induced nephrotoxicity and lipid peroxidation in rats

Regulation of aging and oxidative stress pathways in aged pancreatic islets using alpha-lipoic acid

e role of melatonin on chemotherapy-induced reproductive toxicity

Loss of urokinase receptor sensitizes cells to DNA damage and delays DNA repair

Manipulation of molecular pathways and senescence hallmarks by natural compounds in fibroblast cells

Effect of styrene exposure on plasma parameters, molecular mechanisms and gene expression in rat model islet cells

Resveratrol prevents doxorubicin cardiotoxicity through mitochondrial stabilization and the Sirt1 pathway

Catalase and glutathione peroxidase mimics

e role of melatonin on doxorubicin-induced cardiotoxicity: a systematic review

Role of endothelium in doxorubicin-induced cardiomyopathy

Impact of oxidative stress on the heart and vasculature: Part 2 of a 3-Part Series

Mechanistic links between oxidative/nitrosative stress and tumor necrosis factor alpha in letrozole-induced murine polycystic ovary

Curcumin: from ancient medicine to current clinical trials

Doxorubicin-induced apoptosis: implications in cardiotoxicity

Modulation of apoptosis by melatonin for improving cancer treatment efficiency: an updated review

P9. Correlation of radiation induced apoptosis with Bax and Bcl-2 protein expression

Role of p53, Bax, p21, and DNA-PKcs in radiation sensitivity of HCT-116 cells and xenografts

Small molecule inhibition of MDM2-p53 interaction augments radiation response in human tumors

Predictive value of p53, Bcl2 and bax in the radiotherapy of head and neck cancer

p53 mutation decreased radiosensitivity in rat yolk sac tumor cell lines

p53-Mediated gene activation in mice at high doses of chronic low-dose-rate c radiation

Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models

Ceramide signaling in apoptosis

Alpha-Lipoic acid ameliorates radiation-induced lacrimal gland injury through NFAT5-dependent signaling

Radiation induced apoptosis of murine bone marrow cells is independent of early growth response 1 (EGR1)

Dual effect of p53 on radiation sensitivity in vivo: p53 promotes hematopoietic injury, but protects from gastro-intestinal syndrome in mice

Prophylactic supplementation of resveratrol is more effective than its therapeutic use against doxorubicin induced cardiotoxicity

Resveratrol protects cardiomyocytes from doxorubicin-induced apoptosis through the AMPK/P53 pathway

Resveratrol attenuates doxorubicin-induced cardiomyocyte apoptosis in mice through SIRT1-mediated deacetylation of p53

Stabilization of mitochondrial membrane potential prevents doxorubicininduced cardiotoxicity in isolated rat heart

Resveratrol attenuates doxorubicin-induced cardiomyocyte death via inhibition of p70 S6 kinase 1-mediated autophagy

Alltrans retinoic acid protects against doxorubicin-induced cardiotoxicity by activating the ERK2 signalling pathway

AMP-activated protein kinase α2 and E2F1 transcription factor mediate doxorubicin-induced cytotoxicity by forming a positive signal loop in mouse embryonic fibroblasts and non-carcinoma cells

Functions of poly(ADP-ribose) polymerase (PARP) in DNA repair, genomic integrity and cell death

Taurine suppresses doxorubicin-triggered oxidative stress and cardiac apoptosis in rat via up-regulation of PI3-K/Akt and inhibition of p53, p38-JNK

Antiproliferation and apoptosis induced by curcumin in human ovarian cancer cells

Curcumin induces apoptosis in human breast cancer cells through p53-dependent Bax induction

Mechanism of apoptosis induced by curcumin in colorectal cancer

Curcumin induces apoptosis-independent death in oesophageal cancer cells

Protective effect of curcumin on chemotherapy-induced intestinal dysfunction

Chemotherapy-enhanced inflammation may lead to the failure of therapy and metastasis

Molecular pathways linking inflammation and cancer

Liposomal resveratrol and/or carvedilol attenuate doxorubicin-induced cardiotoxicity by modulating inflammation, oxidative stress and S100A1 in rats

Different effects of resveratrol on dose-related Doxorubicin-induced heart and liver toxicity

Protective effect of resveratrol against doxorubicininduced cardiac toxicity and fibrosis in male experimental rats

Potential pharmacological control of the NF-κB pathway

Rutin ameliorates cyclophosphamide induced oxidative stress and inflammation in Wistar rats: role of NFκB/MAPK pathway

erapeutic effects of silymarin and naringin on methotrexate-induced nephrotoxicity in rats: biochemical evaluation of anti-inflammatory, antiapoptotic, and antiautophagic properties

Pathophysiologically relevant concentrations of tumor necrosis factorα promote progressive left ventricular dysfunction and remodeling in rats

Interleukin-1 blocking agents as promising strategy for prevention of anticancer drug-induced cardiotoxicities: possible implications in cancer patients with COVID-19

TGF-β1 and radiation fibrosis: a master switch and a specific therapeutic target?

Topically applied melatonin ameliorates radiation-induced skin fibrosis in mice

TGF-β receptor I/II trafficking and signaling at primary cilia are inhibited by ceramide to attenuate cell migration and tumor metastasis

Curcumin: an anti-inflammatory molecule from a curry spice on the path to cancer treatment

e authors declare that they have no conflicts of interest.

Q.Zh. gave the idea, edited the original draft manuscript, and supervised the whole study. L.W. performed the literature search, prepared the manuscript, and drafted the figures. All authors read and approved the manuscript.